RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi®… Read More
Related Post
Partnership with Global Technology Investor and Accelerator Leader Highlights Commitment to Real Estate Industry Innovation
HO CHI MINH, Vietnam, Jan. 17, 2018 (GLOBE NEWSWIRE) — Vietnam will host Vietnam Blockchain
Ascom secures an agreement with the Integrated Delivery Network (IDN) Munson Healthcare to upgrade its

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi®… Read More
Related Post
Partnership with Global Technology Investor and Accelerator Leader Highlights Commitment to Real Estate Industry Innovation
HO CHI MINH, Vietnam, Jan. 17, 2018 (GLOBE NEWSWIRE) — Vietnam will host Vietnam Blockchain
Ascom secures an agreement with the Integrated Delivery Network (IDN) Munson Healthcare to upgrade its